PRGO PERRIGO Co plc
Pharmaceutical Preparations · NYSE · SEC CIK 1585364 · Fiscal year ends 12/31
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.5%
TTM net income YoY-3,316.4%
TTM EPS YoY-3,351.4%
Revenue 3-yr CAGR-4.2%
Net income 3-yr CAGR—
Margins
Gross margin32.3%
Operating margin-39.4%
Net margin-43.3%
FCF margin4.1%
EBITDA margin-33.6%
Returns
ROE-51.4%
ROA-20.1%
ROIC (approx.)-19.7%
Asset turnover0.47x
Leverage & solvency
Liabilities / assets67.4%
Debt / equity1.35x
Current ratio2.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.14x
Accruals ratio-22.9%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.25B | $4.37B |
| Cost of revenue | $2.76B | $2.83B |
| Gross profit | $1.49B | $1.54B |
| R&D expense | $95.40M | $112.20M |
| SG&A expense | $435.90M | $468.00M |
| Operating income | -$1.12B | $112.90M |
| Pretax income | -$1.30B | -$80.70M |
| Income tax | $104.40M | $80.00M |
| Net income | -$1.43B | -$171.80M |
| EBITDA | -$784.70M | $438.80M |
| EPS (basic) | -10.29 | -1.25 |
| EPS (diluted) | -10.29 | -1.25 |
| Dividends declared per share | 1.16 | 1.10 |
| Weighted avg. shares (diluted) | 138.50M | 137.40M |
| Balance sheet | ||
| Cash & equivalents | $531.60M | $558.80M |
| Receivables | $612.80M | $642.30M |
| Inventory | $1.15B | $1.08B |
| Current assets | $2.80B | $2.48B |
| PP&E, net | $898.70M | $917.80M |
| Goodwill | $2.05B | $3.32B |
| Intangibles | $4.76B | $4.50B |
| Total assets | $8.54B | $9.65B |
| Current liabilities | $1.01B | $1.04B |
| Short-term debt | $36.60M | $36.40M |
| Long-term debt | $3.60B | $3.58B |
| Total debt | $3.64B | $3.62B |
| Total liabilities | $5.60B | $5.33B |
| Shareholders' equity | $2.94B | $4.32B |
| Net debt | $3.11B | $3.06B |
| Shares outstanding | 137.60M | 136.50M |
| Cash flow statement | ||
| Operating cash flow | $238.50M | $362.90M |
| Capital expenditure | $93.40M | $118.30M |
| Free cash flow | $145.10M | $244.60M |
| Investing cash flow | -$75.40M | $78.80M |
| Financing cash flow | -$220.50M | -$611.00M |
| Depreciation & amortization | $337.50M | $325.90M |
| Stock-based compensation | $54.60M | $64.40M |
| Dividends paid | $159.30M | $152.50M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.